PREVENT与SCORE2心血管风险方程在640万个体中的跨国验证
本研究在44个观察性队列和18项随机试验中验证PREVENT与SCORE2心血管风险方程的区分度和校准度,覆盖北美、欧洲和亚洲/其他地区。平均随访5.1年,分别观察到293,737例PREVENT总CVD事件和258,086例SCORE2 CVD事件。两方程整体区分度和校准度相似,跨区域表现良好,支持在多样环境中采用PREVENT或SCORE2进行心血管风险分层。
要点
- PREVENT和SCORE2在跨区域队列和随机试验中整体区分度与校准度相似。
- 两方程在北美、欧洲和亚洲/其他地区均表现良好,包括多区域随机试验。
- 基于PREVENT方程建立了1-9年风险预测的缩放因子,可用于短期风险预测。
核心结论
- PREVENT与SCORE2方程在多样环境中整体区分度和校准度相似,支持采用任一方程进行心血管风险分层。
研究设计与样本
- 在44个观察性队列和18项随机试验中评估PREVENT与SCORE2的区分度和校准度。
- 分析覆盖北美、欧洲和亚洲/其他或多区域试验,PREVENT分析纳入6,422,714人,SCORE2分析纳入5,437,384人。
主要发现
- 平均随访5.1年,观察到293,737例PREVENT总CVD事件(致死和非致死性ASCVD或HF)。
- 平均随访5.1年,观察到258,086例SCORE2 CVD事件(心肌梗死、卒中或心血管死亡)。
- 尽管CVD结局定义、目标人群和预测变量存在差异,两方程整体区分度和校准度相似,跨区域表现总体良好。
关键数值与推荐
- PREVENT方程估计30-79岁人群的总CVD、ASCVD和HF风险,用于指导降脂和降压治疗。
- SCORE2算法估计40岁及以上人群的CVD风险,用于类似目的。
- 基于PREVENT方程创建了1-9年风险预测的缩放因子,可用于研究或促进临床试验入组。
临床怎么用
- 在多样临床环境中可采用PREVENT或SCORE2进行心血管风险分层。
- PREVENT方程可用于30-79岁人群的总CVD、ASCVD和HF风险评估以指导降脂降压治疗。
- SCORE2可用于40岁及以上人群的CVD风险评估。
- 基于PREVENT的1-9年缩放因子可用于短期风险预测或临床试验入组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The American Heart Association's PREVENT equations estimate risk of total cardiovascular disease (CVD), atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) to guide lipid-lowering and blood pressure-lowering therapy in people ages 30-79 years in the United States. The SCORE2 risk algorithm is used to estimate CVD risk for similar purposes in people ages 40 and older in Europe. Neither set of equations has been comprehensively validated in global observational cohorts and randomized trials. In this study, in 44 observational cohorts and 18 randomized trials, we assessed discrimination and calibration of the two risk algorithms across geographical regions (North America, Europe and Asia/Other or multiregional trials). We also created scaling factors for risk prediction over 1-9 years using the PREVENT equations, enabling shorter-term risk prediction for research purposes or to facilitate clinical trial enrollment. Over 5.1 years of mean follow-up, 293,737 PREVENT total CVD events (fatal and non-fatal ASCVD or HF) and 258,086 SCORE2 CVD events (myocardial infarction, stroke or cardiovascular death) were observed among 6,422,714 and 5,437,384 individuals, respectively. Despite differences in CVD outcome definitions, target populations and predictor variables, overall discrimination and calibration were similar for both equations, with generally good performance across regions, including in multiregional randomized trials. These findings lend support for adoption of PREVENT or SCORE2 for cardiovascular risk stratification across diverse settings.
引用
- Neuen BL, Major RW, Grams ME, et al. Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals. Nat Med. 2026. PMID: 42086979. doi:10.1038/s41591-026-04437-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。